The US Food and Drug Administration is seeking legislative changes that would permit it to approve generic drug-device combination products with “certain differences” in the device component compared to the brand.
The push is one of a handful of legislative asks intended to enhance generic competition included in the Biden...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?